Dermatol. praxi. 2022;16(4):231-234 | DOI: 10.36290/der.2022.047

Bimekizumab - new biological drug in the treatment of psoriasis

MUDr. Jan Šternberský, Ph.D.1, 2, MUDr. Martin Tichý, Ph.D.1, 2
1 Klinika chorob kožních a pohlavních, Lékařská fakulta, Univerzita Palackého v Olomouci
2 Klinika chorob kožních a pohlavních, Fakultní nemocnice Olomouc

In the therapy of psoriasis, we have a whole range of very effective biological drugs available on our market. Bimekizumab, an inhibitor of interleukin 17 (IL-17), is a new preparation that expands our options for the effective treatment of moderate to severe forms of chronic plaque psoriasis in adult patients. Bimekizumab has demonstrated its high effectiveness, rapid onset of action and favorable safety profile in a number of clinical studies.

Keywords: bimekizumab, interleukin 17, inhibitor IL-17, psoriasis.

Accepted: November 29, 2022; Published: December 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Šternberský J, Tichý M. Bimekizumab - new biological drug in the treatment of psoriasis. Dermatol. praxi. 2022;16(4):231-234. doi: 10.36290/der.2022.047.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Hercogová J. Léčba psoriázy v dermatologické praxi. Čes. Dermatovenerol. 2018;8:47-51.
    2. Cetkovska P, et al. Přehled současných doporučených postupů pro systémovou "nebiologickou" léčbu psoriázy. Čes-slov Derm. 2017;92:1-52.
    3. Villalpando-Vargas FV, Rivera-Valdés JJ, Alvarado-Navarro A et al. Association between IL-17A, IL-17F and IL-17RA gene polymorphisms and susceptibility to psoriasis and psoriatic arthritis: a meta-analysis. Inflamm Res. 2021 Dec;70(10-12):1201-1210. doi: 10.1007/s00011-021-01514-6. Epub 2021 Oct 27. PMID: 34705056. Go to original source... Go to PubMed...
    4. Ruggiero A, Potestio L, Camela E, et al. Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Psoriasis (Auckl). 2022 Jun 8;12:127-137. doi: 10.2147/PTT.S367744. PMID: 35707807; PMCID: PMC9189155. Go to original source... Go to PubMed...
    5. Tam HKJ, Robinson PC, Nash P. Inhibiting IL-17A and IL-17F in Rheumatic Disease: Therapeutics Help to Elucidate Disease Mechanisms. Curr Rheumatol Rep. 2022 Oct;24(10):310-320. doi: 10.1007/s11926-022-01084-4. Epub 2022 Jul 21. PMID: 35861937; PMCID: PMC9470681. Go to original source... Go to PubMed...
    6. SPC, Bimzelx 160 mg injekční roztok v předplněném peru/injekční stříkačce, datum poslední revize textu 24. 3. 2022
    7. Adams R, Maroof A, Baker T, et al. Bimekizumab, a Novel Humanized IgG1 Antibody That Neutralizes Both IL-17A and IL-17F. Front Immunol. 2020 Aug 21;11:1894. doi: 10.3389/fimmu.2020.01894. PMID: 32973785; PMCID: PMC7473305. Go to original source... Go to PubMed...
    8. SPC, Cosentyx 150 mg injekční roztok v předplněném peru, datum poslední revize textu 20. 1. 2022. Go to original source...
    9. SPC, Taltz 80 mg injekční roztok v předplněném peru, datum poslední revize textu 16. 12. 2021. Go to original source...
    10. SPC, Kyntheum 210 mg injekční roztok v předplněné injekční stříkačce, datum poslední revize textu 22. 7. 2020.
    11. Salavec M. Bezpečnost sekukinumabu v terapii psoriázy. Dermatol. praxi. 2017;11(4):178-181. Go to original source...
    12. Reich K, Papp KA, Blauvelt A, et al. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet. 2021 Feb 6;397(10273):487-498. doi: 10.1016/S0140-6736(21)00125-2. Erratum in: Lancet. 2021 Feb 20;397(10275):670. PMID: 33549193. Go to original source... Go to PubMed...
    13. Gordon KB, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial. Lancet. 2021 Feb 6;397(10273):475-486. doi: 10.1016/S0140-6736(21)00126-4. Erratum in: Lancet. 2021 Mar 27;397(10280):1182. PMID: 33549192. Go to original source... Go to PubMed...
    14. Warren RB, Blauvelt A, Bagel J, et al. Bimekizumab versus Adalimumab in Plaque Psoriasis. N Engl J Med. 2021 Jul 8;385(2):130-141. doi: 10.1056/NEJMoa2102388. Epub 2021 Apr 23. PMID: 33891379. Go to original source... Go to PubMed...
    15. Reich K, Warren RB, Lebwohl M, et al. Bimekizumab versus Secukinumab in Plaque Psoriasis. N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23. PMID: 33891380. Go to original source... Go to PubMed...
    16. Gordon KB, Langley RG, Warren RB, et al. Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis: Pooled Results From Phase 2 and Phase 3 Randomized Clinical Trials. JAMA Dermatol. 2022 Jul 1;158(7):735-744. doi: 10.1001/jamadermatol.2022.1185. PMID: 35544084; PMCID: PMC9096693. Go to original source... Go to PubMed...
    17. Ritchlin CT, Kavanaugh A, Merola JF et al. Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2020 Feb 8;395(10222):427-440. doi: 10.1016/S0140-6736(19)33161-7. PMID: 32035552. Go to original source... Go to PubMed...
    18. Tichy M, Kojanova M, Velackova B et al. Efficacy of switches within the class of IL-17 inhibitors: An analysis of data from the Czech nationwide registry of psoriatic patients receiving biological/targeted therapy (BIOREP). Dermatol Ther. 2022 Oct;35(10):e15772. doi: 10.1111/dth.15772. Epub 2022 Sep 5. PMID: 36065488. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.